Roivant Sciences Ltd (NASDAQ: ROIV) on Monday, plunged -3.14% from the previous trading day, before settling in for the closing price of $11.80. Within the past 52 weeks, ROIV’s price has moved between $9.69 and $13.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 493.24% over the past five years. The company achieved an average annual earnings per share of -114.65%. With a float of $377.04 million, this company’s outstanding shares have now reached $733.33 million.
Let’s look at the performance matrix of the company that is accounted for 908 employees. In terms of profitability, gross margin is 88.77%, operating margin of 3447.71%, and the pretax margin is 3781.64%.
Roivant Sciences Ltd (ROIV) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Roivant Sciences Ltd is 48.21%, while institutional ownership is 67.66%. The most recent insider transaction that took place on Dec 27 ’24, was worth 4,230,000. Before that another transaction happened on Dec 26 ’24, when Company’s Pres&Chief Investment Officer sold 689,495 for $12.01, making the entire transaction worth $8,280,835. This insider now owns 18,836,547 shares in total.
Roivant Sciences Ltd (ROIV) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -114.65% per share during the next fiscal year.
Roivant Sciences Ltd (NASDAQ: ROIV) Trading Performance Indicators
Roivant Sciences Ltd (ROIV) is currently performing well based on its current performance indicators. A quick ratio of 10.43 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 65.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 5.66, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.09 in one year’s time.
Technical Analysis of Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd (NASDAQ: ROIV) saw its 5-day average volume 3.99 million, a negative change from its year-to-date volume of 5.76 million. As of the previous 9 days, the stock’s Stochastic %D was 42.68%. Additionally, its Average True Range was 0.31.
During the past 100 days, Roivant Sciences Ltd’s (ROIV) raw stochastic average was set at 46.01%, which indicates a significant increase from 6.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.60% in the past 14 days, which was higher than the 29.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.88, while its 200-day Moving Average is $11.33. Nevertheless, the first resistance level for the watch stands at $11.68 in the near term. At $11.94, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.09. If the price goes on to break the first support level at $11.27, it is likely to go to the next support level at $11.12. The third support level lies at $10.86 if the price breaches the second support level.
Roivant Sciences Ltd (NASDAQ: ROIV) Key Stats
Market capitalization of the company is 8.18 billion based on 727,950K outstanding shares. Right now, sales total 124,800 K and income totals 4,349 M. The company made 4,480 K in profit during its latest quarter, and -230,180 K in sales during its previous quarter.
